Iovance Biotherapeutics
IOVA
234 hedge funds and large institutions have $4.22B invested in Iovance Biotherapeutics in 2021 Q2 according to their latest regulatory filings, with 45 funds opening new positions, 102 increasing their positions, 57 reducing their positions, and 62 closing their positions.
184% more call options, than puts
Call options by funds: $104M | Put options by funds: $36.6M
79% more repeat investments, than reductions
Existing positions increased: 102 | Existing positions reduced: 57
0% more funds holding in top 10
Funds holding in top 10: 7 → 7 (0)
0.83% less ownership
Funds ownership: 106.9% → 106.08% (-0.83%)
7% less funds holding
Funds holding: 252 → 234 (-18)
15% less capital invested
Capital invested by funds: $4.98B → $4.22B (-$765M)
27% less first-time investments, than exits
New positions opened: 45 | Existing positions closed: 62
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$87.6M |
| 2 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$63.3M |
| 3 |
NAMA
Nikko Asset Management Americas
New York
|
+$61.8M |
| 4 |
PA
Perceptive Advisors
New York
|
+$60M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$44.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$115M |
| 2 |
AllianceBernstein
Nashville,
Tennessee
|
-$58.9M |
| 3 |
BlackRock
New York
|
-$57.4M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$55.8M |
| 5 |
Franklin Resources
San Mateo,
California
|
-$46.4M |
IOVA Hedge Fund Activity: Q2 2021 in Review
234 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Iovance Biotherapeutics (IOVA) for Q2 2021, worth a combined $4.22B — down 15% from $4.98B a quarter earlier.
Sellers outnumbered buyers: 62 funds closed out of IOVA and 45 opened new positions — a net loss of 17 holders — while 57 trimmed existing stakes and 102 added.
The largest buyer was Armistice Capital, opening a new position worth an estimated $87.6M. The largest seller was Deutsche Bank, cutting an estimated $115M.
- 234 institutional investors held Iovance Biotherapeutics (IOVA) as of Q2 2021, down from 252 in Q1 2021.
- Funds reported $4.22B of Iovance Biotherapeutics stock for Q2 2021, down 15% quarter-over-quarter.
- 45 funds opened new Iovance Biotherapeutics positions in Q2 2021 and 62 closed out, a net change of -17 holders.
- The largest Iovance Biotherapeutics buyer in Q2 2021 was Armistice Capital, an estimated $87.6M added.
- The largest Iovance Biotherapeutics seller in Q2 2021 was Deutsche Bank, an estimated $115M sold.
Based on aggregated 13F filings for Q2 2021.